company background image
FRES logo

Fresh2 Group NasdaqCM:FRES Stock Report

Last Price

US$0.69

Market Cap

US$10.0m

7D

89.1%

1Y

-89.4%

Updated

18 Mar, 2024

Data

Company Financials

Fresh2 Group Limited

NasdaqCM:FRES Stock Report

Market Cap: US$10.0m

FRES Stock Overview

Fresh2 Group Limited, a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People’s Republic of China.

FRES fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Fresh2 Group Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Fresh2 Group
Historical stock prices
Current Share PriceUS$0.69
52 Week HighUS$9.17
52 Week LowUS$0.30
Beta1.37
1 Month Change46.81%
3 Month Change-14.25%
1 Year Change-89.43%
3 Year Change-99.48%
5 Year Changen/a
Change since IPO-99.69%

Recent News & Updates

Recent updates

AnPac Bio announces plan to implement ADS ratio change

Oct 18

AnPac Bio-Medical Science announces management changes

Oct 03

AnPac Bio-Medical Science signed equity investment totaling $3.67M with new investor Group

Sep 27

AnPac Bio appoints Yuyang Cui as co-chief executive officer

Aug 05

AnPac Bio stock soars 15% after securing first disease treatment patent in U.S.

Jun 18

AnPac Bio wins new US patent for multi-cancer detection

Feb 01

AnPac Bio (ANPC) skyrockets 136% on advancement in detecting pre-cancer diseases

Dec 14

Industry Analysts Just Upgraded Their AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) Revenue Forecasts By 55%

Dec 11
Industry Analysts Just Upgraded Their AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) Revenue Forecasts By 55%

AnPac Bio-Medical rallies on Q3 record test volume; FY20 revenue estimated at +100%

Nov 25

AnPac Bio's Chinese company secures COVID-19 nucleic acid test certification; shares +33%

Nov 02

Shareholder Returns

FRESUS BiotechsUS Market
7D89.1%-2.1%-0.1%
1Y-89.4%10.4%28.4%

Return vs Industry: FRES underperformed the US Biotechs industry which returned 10.4% over the past year.

Return vs Market: FRES underperformed the US Market which returned 28.4% over the past year.

Price Volatility

Is FRES's price volatile compared to industry and market?
FRES volatility
FRES Average Weekly Movement27.2%
Biotechs Industry Average Movement11.9%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: FRES's share price has been volatile over the past 3 months.

Volatility Over Time: FRES's weekly volatility has increased from 22% to 27% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201075Haohan Xuhttps://fresh2.co

Fresh2 Group Limited, a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People’s Republic of China. It also offers physical checkup packages, as well as technology services comprising market research, designing, coding, developing, testing, etc. In addition, the company sells genetic testing kits and skin-care products; and owns core technology platforms, as well as engages in technology development and product distribution. Further, it operates an e-commerce platform that connects food suppliers and supermarket operators and restaurant owners.

Fresh2 Group Limited Fundamentals Summary

How do Fresh2 Group's earnings and revenue compare to its market cap?
FRES fundamental statistics
Market capUS$10.01m
Earnings (TTM)-US$18.95m
Revenue (TTM)US$2.36m

4.2x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
FRES income statement (TTM)
RevenueCN¥16.98m
Cost of RevenueCN¥7.75m
Gross ProfitCN¥9.23m
Other ExpensesCN¥145.65m
Earnings-CN¥136.42m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-9.40
Gross Margin54.38%
Net Profit Margin-803.40%
Debt/Equity Ratio0.01%

How did FRES perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.